Proprietary Human Clinical Studies:
1. 'In a randomized, double-blinded, placebo controlled 8-week study involving 132 healthy men and women, age between 25 to 55 years, 200mg of Reishi β-glucan helped increase vigor and reduced the scores related to anxiety, depression, fatigue, and mood disturbance. Test subjects used a Profile of Mood States Short Form (POMS-SF) to report their mood state.'
Results:
The results indicated that the group receiving Reishi β-glucan is statistically different than the one receiving placebos in five POMS factors mean scores including Tension-anxiety (p<.05), Vigor-activity (p<.05), Fatigue-activity (p<.05), Depression (p<.05) and mood disturbance (p<.05)
2. 'In an open-labelled, paralleled group, randomly selected, 90 day study, involving 16 men, 11 women, (36±13 yrs) all employees of an accounting firm. 2 groups: Group 1 (given 300mg of Reishi β-glucan) and Group 2 (given 600mg of Reishi β-glucan), were asked to keep track of 9 Upper Respiratory Infection symptoms (URTI) including: headache, tiredness, weakness, fatigue, nasal congestions, sneezing, coughing,
sore throat, and general aches.'
Results:
The results indicated a significant decline in URTI symptoms by both groups, both in the middle and end of study. During the interim analysis (Day 46), a decrease of 34.22% observed in group 2 receiving 600 mg per day, which was higher than 31.71% observed in group 1 receiving 300 mg per day (2.81%, p=.036). During the conclusion of the trial (Day 91), the average reduction in URTI symptoms in group 2 (receiving 600 mg/day) was 46.83%, which is significantly higher than those of in group 1 receiving 300 mg/day (42.68%)
(4.15%, p=.041).
3. ‘In a randomized, double-blinded, placebo controlled 84-day study involving 126 healthy men and women, age between 18 to 55 years, were administered 200mg of Reishi β-glucan. This study’s goal was to confirm immunomodulatory properties of Reishi β-glucan. More specifically that it has both innate and adaptive immune responses due to Reishi β-glucan being a Pathogen recognition receptor agonist (PRR).’
Results:
At the conclusion of the 84-day administration period, blood samples were collected to analyze for primary outcomes, including the impact of Reishi β -glucan on various immune cells (CD3+, CD4+and CD8+ T-lymphocytes, NK cell counts/mediated cytotoxicity and serum IgA levels), as well as secondary outcomes, including various hematological biomarkers (alanine aminotransferase (ALT), aspartate aminotransferase (AST), Creatinine, red blood cell (RBC), hemoglobin (HB), hematocrit(HCT) and platelet counts) to determine the safety and tolerability of the intervention, in order to provide a comprehensive understanding of the effectiveness of
Reishi β-glucan .
The key findings from this study included that Reishi β -glucan induced statistically significant modifications of the CD3+, CD4+, CD8+ T-lymphocytes and NK cells, as well as elicited a statistically significant increase in serum IgA concentration in the Reishi β-glucan group versus placebo.
